Gentian Diagnostics Asa · OSL:GENT
Gentian Diagnostics Asa — Redeye Diagnostics conference 2022
11 slides from Gentian Diagnostics Asa's conference presentation, September 2022
Slide 1: Innovative and efficient diagnostics
Redeye Diagnostics September 2022 Innovative and efficient diagnostics ADDRESSING HIGH-VALUE MARKETS
Slide 2: Important notice
Important notice This presentation has been prepared by and is the sole which are subject to risks, uncertainties and other factors with applicable laws and regulations. The Company require responsibility of Gentian Diagnostics ASA (the “Company” that may cause actual events to differ materially fro
Slide 3: Efficient diagnostics for better treatment decisions
Efficient diagnostics for better treatment decisions The growing diagnostic market puts increasing pressure on laboratories. Still, many of the existing, clinically relevant biomarkers are only available on slow and inefficient platforms. By converting biomarkers to the most efficient automated, hig
Slide 4: Gentian Diagnostics develops and supplies innovative and efficient reagents for the clinical diagnostics market
Gentian Diagnostics develops and supplies innovative and efficient reagents for the clinical diagnostics market Sales office, Sweden • Gentian serves the global market for human and veterinary clinical diagnostic tests HQ, Norway • Expertise and focus within immunochemistry, specifically in the dise
Slide 5: Portfolio of high-impact tests provides solid growth opportunity
Portfolio of high-impact tests provides solid growth opportunity 7* tests contributing Annual revenue to saving costs and ambition of NOK protecting life 1bn in 4-6 years** Ambition to bring a steady USD 1.3bn serviceable stream of high-impact market with 8-9% annual diagnostic tests to market growt
Slide 6: How Gentian contributes to efficient diagnostics for better treatment decisions
How Gentian contributes to efficient diagnostics for better treatment decisions The industry challenge Gentian’s solution High-value benefits A growing diagnostics market puts increasing Particle-enhanced turbidimetric 3-10x higher throughput significantly pressure on clinical laboratory efficiency
Slide 7: Products targeting large and growing disease groups
Products targeting large and growing disease groups DISEASE GROUP PRODUCT APPLICATION ATTRACTIVE CLINICAL BENEFITS Kidney disease Cystatin C Early detection of reduced kidney function Preventing severe kidney failure Inflammation Fast diagnosis of inflammatory bowel disease Reducing time-consuming a
Slide 8: USD 1.3bn global serviceable market estimated to grow by 8-9% annually next 4-6 years
USD 1.3bn global serviceable market estimated to grow by 8-9% annually next 4-6 years Serviceable Market Total Addressable Total Serviceable Target market share, Gentian’s annual growth rate, Market, USDbn Market, USDm unrisked revenue take next 4-6 years Established products 1.5 180 ~25% 30-50% 5-1
Slide 9: Solid progress recent years with sales growth and partnerships with leading global diagnostic companies
Solid progress recent years with sales growth and partnerships with leading global diagnostic companies Total revenue* and CAGR Partnerships prove viability of go-to-market model 120 100 NOKm Global distribution agreement for 100 GCAL®, initial roll-out in Europe 80 +27% 79 60 Long-standing commerci
Slide 10: Long-term ambitions rooted in recent progress
Long-term ambitions rooted in recent progress Four established products with potential to grow 20%+ annually Prove clinical relevance of GCAL and bring NT-proBNP to market 7 products with combined net revenue potential of Bring a steady stream of high-impact diagnostic tests to market Revenue NOK 1b
Slide 11: Thank you!
Thank you!
Gentian Diagnostics — Redeye Diagnostics conference 2022 on 6ix